Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02986945 · ClinicalTrials.gov registry record · NA
Community-Partnered Participatory Development of Mobile Interventions
A NA study, sponsored by RAND.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT02986945: Completed NA study, sponsored by RAND.
NCT02986945 is a NA study that has completed, run by RAND. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02986945, a NA study, has completed, sponsored by RAND.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of the study is to test an experimental method, a text-messaging app called B-RESILIENT, for improving participants' mood. B-RESILIENT is a text messaging app adaptation of a Resiliency Course, developed by community members known as Building Resiliency and Community Hope.
Primary Outcome
The Patient Health Questionnaire (PHQ) 8 is a standard measure of depressive symptoms.
Interventions
- BEHAVIORAL Resiliency App
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-12-01 |
| Est. Completion | 2017-03-28 |
| Phase | NA |
What the finished NCT02986945 record still lists
NCT02986945 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Resiliency App is the first listed.
NCT02986945 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02986945 about?
NCT02986945 is a clinical study titled "Community-Partnered Participatory Development of Mobile Interventions". The purpose of the study is to test an experimental method, a text-messaging app called B-RESILIENT, for improving participants' mood. B-RESILIENT is a text messaging app adaptation of a Resiliency Course, developed by community members known as Building Resiliency and Community Hope.
What is the current status of trial NCT02986945?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2016-12-01. Estimated completion is 2017-03-28.
What interventions are being tested in trial NCT02986945?
The interventions under investigation include: Resiliency App (BEHAVIORAL).
Who is sponsoring clinical trial NCT02986945?
This trial is sponsored by RAND, which has 78 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02986945's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI